PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

The following is a summary of “Prevalence of Mast Cell Activation Disorders and Hereditary Alpha Tryptasemia Amongst POTS and ...

According to the American College of Allergy Asthma and Immunology, nearly one in three U.S. adults report having a seasonal ...

Tumors develop when cells in the body grow uncontrollably. Finding a tumor on your dog can be very frightening, but they are ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high valuation and future drug risks.

Jasper Therapeutics, Inc.’s JSPR share price has surged by 7.55%, which has investors questioning if this is right time to sell.

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...

Readers reply to an essay on overdiagnosis in medicine.

This spring, Newsweek takes a closer look at the role mast cells play in seasonal and other ... citing data from the Centers for Disease Control and Prevention (CDC), nearly one in three U.S ...

A modern Western diet, high in processed foods and low in whole plant-based foods, can contribute to chronic inflammation but ...